RU2017128308A3 - - Google Patents

Download PDF

Info

Publication number
RU2017128308A3
RU2017128308A3 RU2017128308A RU2017128308A RU2017128308A3 RU 2017128308 A3 RU2017128308 A3 RU 2017128308A3 RU 2017128308 A RU2017128308 A RU 2017128308A RU 2017128308 A RU2017128308 A RU 2017128308A RU 2017128308 A3 RU2017128308 A3 RU 2017128308A3
Authority
RU
Russia
Application number
RU2017128308A
Other languages
Russian (ru)
Other versions
RU2017128308A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017128308A publication Critical patent/RU2017128308A/ru
Publication of RU2017128308A3 publication Critical patent/RU2017128308A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2017128308A 2015-01-14 2016-01-14 Синтез ингибитора тирозинкиназы брутона RU2017128308A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Publications (2)

Publication Number Publication Date
RU2017128308A RU2017128308A (ru) 2019-02-14
RU2017128308A3 true RU2017128308A3 (https=) 2019-10-24

Family

ID=56406389

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017128308A RU2017128308A (ru) 2015-01-14 2016-01-14 Синтез ингибитора тирозинкиназы брутона

Country Status (16)

Country Link
US (6) US20180009814A1 (https=)
EP (1) EP3245208A4 (https=)
JP (2) JP2018502077A (https=)
KR (1) KR20170102887A (https=)
CN (2) CN107108640A (https=)
AU (2) AU2016206693A1 (https=)
BR (1) BR112017015206B1 (https=)
CA (2) CA3210320A1 (https=)
HK (1) HK1246293A1 (https=)
IL (4) IL322449A (https=)
MA (1) MA41350A (https=)
MX (2) MX394327B (https=)
RU (1) RU2017128308A (https=)
SG (2) SG10201906517VA (https=)
WO (1) WO2016115356A1 (https=)
ZA (1) ZA201704338B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6681922B2 (ja) * 2015-02-12 2020-04-15 上▲海▼度▲徳▼医▲藥▼科技有限公司 イブルチニブの製造方法
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
WO2019027860A1 (en) 2017-08-01 2019-02-07 Boehringer Ingelheim International Gmbh INTERMEDIATE COMPOUNDS AND METHODS
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
JP6918204B2 (ja) 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
KR20210044736A (ko) 2018-05-03 2021-04-23 주노 쎄러퓨티크스 인코퍼레이티드 키메라 항원 수용체(car) t세포 요법과 키나제 억제제의 조합요법
JP6944496B2 (ja) * 2018-10-22 2021-10-06 ファイザー・インク ピロロ[2,3−d]ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
KR102742083B1 (ko) 2018-11-09 2024-12-16 다이호야쿠힌고교 가부시키가이샤 디메톡시벤젠 화합물의 제조 방법
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希(南京)药物研发有限公司 一种依鲁替尼-d5的制备方法
KR20220011669A (ko) 2019-05-21 2022-01-28 얀센 파마슈티카 엔.브이. Btk 억제제 제조를 위한 방법 및 중간체
WO2020234381A1 (en) 2019-05-21 2020-11-26 Janssen Pharmaceutica Nv Processes and intermediates for preparing a btk inhibitor
US20240092785A1 (en) 2021-01-21 2024-03-21 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
MXPA06007326A (es) * 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
DK2526933T3 (en) * 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
JP6261580B2 (ja) * 2012-07-30 2018-01-17 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化イブルチニブ
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
US10266535B2 (en) * 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof

Also Published As

Publication number Publication date
HK1246293A1 (zh) 2018-09-07
MX394327B (es) 2025-03-24
BR112017015206B1 (pt) 2023-04-11
US20220098200A1 (en) 2022-03-31
CN113816962A (zh) 2021-12-21
JP2018502077A (ja) 2018-01-25
SG11201705678YA (en) 2017-08-30
CA2971460A1 (en) 2016-07-21
IL322449A (en) 2025-09-01
JP2021035947A (ja) 2021-03-04
CN107108640A (zh) 2017-08-29
MA41350A (fr) 2017-11-21
WO2016115356A1 (en) 2016-07-21
ZA201704338B (en) 2023-10-25
IL274716A (en) 2020-07-30
BR112017015206A2 (pt) 2018-06-19
KR20170102887A (ko) 2017-09-12
US20180009814A1 (en) 2018-01-11
IL253020A0 (en) 2017-08-31
US20240158400A1 (en) 2024-05-16
SG10201906517VA (en) 2019-08-27
RU2017128308A (ru) 2019-02-14
MX366827B (es) 2019-07-25
IL308276A (en) 2024-01-01
CA2971460C (en) 2023-10-10
EP3245208A4 (en) 2018-10-17
US20250197404A1 (en) 2025-06-19
US20190367518A1 (en) 2019-12-05
AU2016206693A1 (en) 2017-07-13
CA3210320A1 (en) 2016-07-21
MX2019008815A (es) 2019-09-26
EP3245208A1 (en) 2017-11-22
AU2020230323A1 (en) 2020-10-01
US20200347064A1 (en) 2020-11-05
MX2017009154A (es) 2017-10-12

Similar Documents

Publication Publication Date Title
BR112017026363A2 (https=)
RU2017128308A3 (https=)
BR0009761B1 (https=)
BR0009717B1 (https=)
CN303070285S (https=)
CN303068748S (https=)
CN303067337S (https=)
CN303066945S (https=)
BR9908450B1 (https=)
BR9906735B1 (https=)
BR0304453B1 (https=)
BR0211191B1 (https=)
BR0009994B1 (https=)
BR0009942B1 (https=)
BR0009757B1 (https=)
BR0009649B1 (https=)
BR0009373B1 (https=)
BR0009349B1 (https=)
BR0009182B1 (https=)
BR0008874B1 (https=)
BR0008789B1 (https=)
BR0008719B1 (https=)
BR0008604B1 (https=)
BR0008158B1 (https=)
BR0008132B1 (https=)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20220111